Intermediate dose cyclophosphamide combined with a growth factor is a safe and effective regimen for mobilisation of peripheral blood progenitor cells

Aust N Z J Med. 1996 Jun;26(3):411-3. doi: 10.1111/j.1445-5994.1996.tb01931.x.
No abstract available

Publication types

  • Clinical Trial
  • Clinical Trial, Phase II

MeSH terms

  • Adult
  • Antineoplastic Agents, Alkylating / administration & dosage*
  • Cyclophosphamide / administration & dosage*
  • Female
  • Granulocyte Colony-Stimulating Factor / administration & dosage*
  • Hematopoietic Stem Cell Transplantation*
  • Hematopoietic Stem Cells / drug effects*
  • Hodgkin Disease / therapy*
  • Humans
  • Leukapheresis
  • Lymphoma, Non-Hodgkin / therapy*
  • Male
  • Transplantation Conditioning

Substances

  • Antineoplastic Agents, Alkylating
  • Granulocyte Colony-Stimulating Factor
  • Cyclophosphamide